| Secondary |
| Drug Use For Unknown Indication |
27.7% |
| Product Used For Unknown Indication |
9.0% |
| B-cell Lymphoma |
6.6% |
| Helicobacter Infection |
5.5% |
| Hypertension |
4.4% |
| Infection Prophylaxis |
4.4% |
| Atypical Mycobacterial Infection |
3.8% |
| Diabetes Mellitus |
3.6% |
| Insomnia |
3.6% |
| Prophylaxis |
3.6% |
| Rheumatoid Arthritis |
3.6% |
| Back Pain |
3.3% |
| Hypoaesthesia |
3.3% |
| Upper Respiratory Tract Inflammation |
3.0% |
| Cough |
2.7% |
| Productive Cough |
2.7% |
| Nasopharyngitis |
2.5% |
| Pharyngitis |
2.5% |
| Bronchitis |
2.2% |
| Hyperlipidaemia |
2.2% |
|
| Pseudomembranous Colitis |
11.3% |
| Hepatic Function Abnormal |
7.5% |
| Liver Injury |
7.5% |
| Rhabdomyolysis |
7.5% |
| Thrombocytopenia |
7.5% |
| Melaena |
5.7% |
| Pneumonia |
5.7% |
| Agranulocytosis |
3.8% |
| Drug-induced Liver Injury |
3.8% |
| Erythema |
3.8% |
| Haematochezia |
3.8% |
| Ileus |
3.8% |
| Liver Disorder |
3.8% |
| Neutropenia |
3.8% |
| Oral Mucosa Erosion |
3.8% |
| Organising Pneumonia |
3.8% |
| Pneumatosis Intestinalis |
3.8% |
| Prothrombin Time Shortened |
3.8% |
| Pyrexia |
3.8% |
| Anaphylactic Shock |
1.9% |
|
| Concomitant |
| Rheumatoid Arthritis |
25.6% |
| Prophylaxis |
14.3% |
| Product Used For Unknown Indication |
13.6% |
| Drug Use For Unknown Indication |
7.7% |
| Hypertension |
5.1% |
| Chronic Hepatitis C |
3.5% |
| Gastritis Prophylaxis |
3.4% |
| Prophylaxis Against Gastrointestinal Ulcer |
2.6% |
| Hepatitis C |
2.6% |
| Gastritis |
2.5% |
| Premedication |
2.3% |
| Constipation |
2.2% |
| Osteoporosis |
2.1% |
| Multiple Myeloma |
2.1% |
| Insomnia |
2.1% |
| Aplastic Anaemia |
1.8% |
| Diabetes Mellitus |
1.7% |
| Adverse Event |
1.7% |
| Infection Prophylaxis |
1.6% |
| Pain |
1.6% |
|
| White Blood Cell Count Decreased |
12.8% |
| Pyrexia |
9.6% |
| Interstitial Lung Disease |
7.9% |
| Subarachnoid Haemorrhage |
7.8% |
| Pneumonia |
7.1% |
| Vomiting |
7.1% |
| Rash |
6.9% |
| Renal Impairment |
5.2% |
| Malaise |
3.9% |
| Platelet Count Decreased |
3.4% |
| Urinary Tract Infection |
3.4% |
| Liver Disorder |
3.2% |
| Cerebral Infarction |
2.9% |
| Hepatic Function Abnormal |
2.9% |
| Pneumocystis Jiroveci Pneumonia |
2.9% |
| Respiratory Failure |
2.9% |
| Sepsis |
2.5% |
| Somnolence |
2.5% |
| Tuberculosis |
2.5% |
| White Blood Cell Count Increased |
2.5% |
|
| Interacting |
| Rheumatoid Arthritis |
56.3% |
| Prophylaxis |
21.9% |
| Gastrointestinal Disorder |
18.8% |
| Graft Versus Host Disease |
3.1% |
|
| Rash |
85.7% |
| Drug-induced Liver Injury |
14.3% |
|
